The discovery in 2001 of a G protein-coupled receptor family, subsequently termed trace amine-associated receptors (TAAR), triggered a resurgence of interest in so-called trace amines. Initial optimism quickly faded, however, as the TAAR family presented a series of challenges preventing the use of standard medicinal chemistry and pharmacology technologies. Consequently the development of basic tools for probing TAAR and translating findings from model systems to humans has been problematic. Despite these challenges the last 5 years have seen considerable advances, in particular with respect to TAAR1, which appears to function as an endogenous rheostat, maintaining central neurotransmission within defined physiological limits, in part through receptor heterodimerization yielding biased signaling outputs. Regulation of the dopaminergic system is particularly well understood and clinical testing of TAAR1 directed ligands for schizophrenia and psychiatric disorders have begun. In addition, pre-clinical animal models have identified TAAR1 as a novel target for drug addiction and metabolic disorders. Growing evidence also suggests a role for TAARs in regulating immune function. This review critically discusses the current state of TAAR research, highlighting recent developments and focussing on human TAARs, their functions, and clinical implications. Current gaps in knowledge are identified, along with the research reagents and translational tools still required for continued advancement of the field. Through this, a picture emerges of an exciting field on the cusp of significant developments, with the potential to identify new therapeutic leads for some of the major unmet medical needs in the areas of neuropsychiatry and metabolic disorders.
Introduction
Interest in the therapeutic potential of trace amines has spanned over 50 years. The term trace amine was originally coined to represent any endogenous (mono)amine with physiological levels below 100 ng/g tissue (Boulton, 1974) , approximately two orders of magnitude lower than the aminergic neurotransmitters dopamine, noradrenaline, and serotonin (Berry, 2004; Grandy, 2007) . As initial trace amine research focussed largely on p-tyramine, 2-phenylethylamine, and to a lesser extent tryptamine and p-octopamine, the term subsequently became synonymous with these compounds. These initial research efforts stalled, however, through a combination of a focus on the "false neurotransmitter", amphetamine-like, indirect sympathomimetic action of ptyramine and 2-phenylethylamine at plasma membrane monoamine transporters, and the lack of a receptor target for other effects. Consequently, by the early-1990s virtually all trace amine research had ceased. This changed 15 years ago when two groups independently identified a family of G protein-coupled receptors (GPCRs), a sub-set of which were selectively activated by p-tyramine and 2-phenylethylamine, with tryptamine and p-octopamine also showing agonistic activity (Borowsky et al., 2001; Bunzow et al., 2001 ). As will be discussed in subsequent sections, current research suggests, however, that a return to the original intent of the term trace amine is warranted, as additional receptor family members are activated by endogenous amines outside of the more narrow definition of trace amines that has come into general use.
Another area of contention relates to the multiple terminologies that have been used to describe these receptors. Following their initial discovery different groups employed different nomenclature systems, with the receptor family variously referred to as TA (Borowsky et al., 2001) , TAR (Bunzow et al., 2001) , and TRAR (Duan et al., 2004) , and little consistency in the numbering of individual subtypes. This was resolved in 2005, when a unifying nomenclature, trace amine-associated receptors (TAARs), was proposed . The TAAR classification was supported by a strong rationale based on genomic organization, gene sequences, and phylogenetic relationships between different family members, which has subsequently been independently verified by multiple groups (Azzouzi, Barloy-Hubler, & Galibert, 2015; Eyun, Moriyama, Hoffmann, & Moriyama, 2016; Gao et al., 2016; Hashiguchi & Nishida, 2007; Hussain, Saraiva, & Korsching, 2009; Libants et al., 2009; Tessarolo, Tabesh, Nesbitt, & Davidson, 2014; Vallender, Xie, Westmoreland, & Miller, 2010) . Further, the proposed nomenclature recognized the important confound that not all family members responded to the classical, limited group of trace amines. It is thus not surprising that the TAAR nomenclature proposed by Lindemann and colleagues has been widely accepted, and is now more or less the default nomenclature used within the literature. Despite the uniform use of the TAAR system for over a decade by those active in the field, currently the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) has adopted TA 1 as the name of the only family member that has been de-orphanized (Alexander et al., 2015; Maguire et al., 2009) . This is based partly on the argument and adherence to convention that the names of receptor proteins be based on the name of the endogenous ligand. Unfortunately this is prone to confusion with the original TA designation (Borowsky et al., 2001) , whose numbering of individual family members was not based on a full phylogenetic analysis. For example TA 2 and TA 4 of Borowsky et al. corresponds to TAAR4 and TAAR6 respectively of Lindemann and colleagues. For consistency and clarity it is necessary to resolve this discrepancy through renewed dialogue between the leading researchers in the trace amine field and IUPHAR. Consistent with the current practices in the trace amine field we have used the nomenclature proposed by throughout this review.
Even with a family of receptors identified initial progress in the field was slow. Researchers struggled to come to grips with many unique and challenging aspects of TAARs including low expression levels (Babusyte, Kotthoff, Fiedler, & Krautwurst, 2013; Borowsky et al., 2001; Dinter, Muhlhaus, Wienchol et al., 2015; Ito et al., 2009; Raab et al., 2016; Revel et al., 2013) , high species variability in the functional TAAR complement (Eyun et al., 2016; Gloriam, Bjarnadottir, Schioth, & Fredriksson, 2005; Hashiguchi & Nishida, 2007) , preferential intracellular location of the receptors (Bunzow et al., 2001; Miller et al., 2005; Raab et al., 2016) , broad ligand tuning of the receptors (Bunzow et al., 2001; Ferrero et al., 2012; Pacifico, Dewan, Cawley, Guo, & Bozza, 2012; Saraiva et al., 2016; Zhang, Pacifico, Cawley, Feinstein, & Bozza, 2013) , and the lack of a single consensus ligand that defines the family as a whole (Ferrero et al., 2012; . These, and other factors, have conspired to make TAARs resistant to traditional medicinal chemistry approaches, frustrating and confounding researchers, and leading to the receptors being referred to in such colourful terms as 'iconoclast' (Grandy, 2007) and 'protean' (Burchett & Hicks, 2006) . Despite these challenges being identified as long ago as 2005 , the development of high quality, commercially available, selective reagents to further probe the system has been slow, further hindering progress. Through the dedicated work of a small number of groups these limitations have now begun to be overcome. This entire group was brought together for the first time at the 23rd International Stress & Behaviour Conference (St. Petersburg, Russia) in May 2016. From this meeting genuine optimism emerged that the TAAR field is on the cusp of significant breakthroughs, including identifying new therapeutic targets for some of the largest unmet medical needs. Such developments are the focus of the current article. While a brief background to the field is provided, we will focus on the recent developments that have occurred since 2010, while also identifying the challenges that still remain to be addressed. For a more thorough discussion of the history and background to the trace amine field the reader is referred to earlier excellent and thorough review articles that link the earlier trace amine work to the initial characterization of TAARs (Berry, 2004; Grandy, 2007) . Since this review focuses on the therapeutic potential of TAAR we will primarily restrict discussion to those TAARs for which there is a functional human isoform.
The Human TAAR Family
TAARs are a family of vertebrate, rhodopsin-like, type A, GPCR (Borowsky et al., 2001; Bunzow et al., 2001) . Although up to 26 subtypes of TAAR have been identified in mammalian species (Eyun et al., 2016; Hashiguchi & Nishida, 2007; Hussain et al., 2009) , they all belong to nine sub-families (TAAR1-9) (Gloriam et al., 2005; Hashiguchi & Nishida, 2007; . Within these nine sub-families repeated species specific expansions and pseudogenization events have occurred giving rise to species-specific isoforms and a large variation in the functional TAAR complement present between species (Eyun et al., 2016; Shi et al., 2016; Vallender et al., 2010) . Humans express a single functional variant of 6 of the TAAR family members (TAAR1, 2, 5, 6, 8 and 9) (Table 1) , with TAAR3, 4 and 7 subtypes appearing to be pseudogenes . Consequently, while there is a body of literature concerning the physiology and pharmacology of TAAR3, 4, and 7 in typical laboratory species, this will not be discussed in the current review. The key features of the human TAAR family that are expanded upon throughout this manuscript are summarized in Table 1 .
Human TAAR genes
In mammals, TAAR genes are arranged as a single cluster on an individual chromosome, with the human cluster mapping to chromosome 6q23.2 (Borowsky et al., 2001; Bunzow et al., 2001 ). This position may have therapeutic relevance as it coincides with a putative susceptibility locus for schizophrenia (Cao et al., 1997; Kaufmann et al., 1998; Levinson et al., 2000) and affective disorders (Venken et al., 2005) . Whilst TAARs were not among the 108 genes recently identified by a large genome-wide association study focusing on schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), a recent study has reported an association of rare TAAR1 variants with schizophrenia (John et al., 2017) . In addition, the TAAR1 gene has been identified as a risk factor for fibromyalgia (Smith et al., 2012) and function modifying polymorphisms of human TAAR1 have recently been reported (Shi et al., 2016) .
Each TAAR gene consists of a single exon, with the exception of TAAR2 which contains two exons (Table 1) . TAARs are only distantly related to GPCRs for the classical monoamine neurotransmitters dopamine, noradrenaline and 5-hydroxytryptamine, with the closest outgroup the 5HT 4 pseudogene (Borowsky et al., 2001; Eyun et al., 2016; Hashiguchi & Nishida, 2007; . Indeed the initial discovery of TAAR was in part a result of a search for novel 5HT receptors (Borowsky et al., 2001) . Importantly TAARs are not present in invertebrates (Gloriam et al., 2005; and are evolutionarily distinct from the invertebrate tyramine and octopamine receptors. This restricts TAAR research to vertebrate systems, making many excellent model systems in Drosophila and C. elegans unsuitable for use. The common ancestor of TAARs arose within the vertebrate lineage, although whether this was before (Hashiguchi & Nishida, 2007; Libants et al., 2009) or after (Hussain et al., 2009; Tessarolo et al., 2014 ) the divergence of lamprey is a matter of some debate. Notwithstanding this, TAARs are widely accepted as being under strong positive selection pressure (Hussain et al., 2009; Vallender et al., 2010) , suggesting that evolutionarily they function in adaptive responses. Indeed, evidence has begun to be accumulated that the TAAR expression profile can be influenced by habitat changes, at least in some species (Churcher, Hubbard, Marques, Canario, & Huertas, 2015; Fatsini, Bautista, Manchado, & Duncan, 2016) .
In humans, defunctionalizing single nucleotide polymorphisms of TAAR2 (Bly, 2005) and TAAR9 (Muller et al., 2010; Vanti et al., 2003) have been reported in up to 20% of the population, although these studies do not appear to have been replicated and their clinical relevance is unclear. In addition to the putative function modifying TAAR1 variants recently linked to schizophrenia (John et al., 2017) , various single nucleotide polymorphisms (Chang et al., 2015; Duan et al., 2004) and other variants (Pae et al., 2010) of TAAR6 have also been reported, and these have been suggested to be linked to aetiology and treatment outcomes in both schizophrenia (Duan et al., 2004) and affective disorders (Abou Jamra et al., 2005; Pae, Drago et al., 2008; Pae et al., 2010) , and corticosterone response in asthma (Chang et al., 2015) .
Tissue expression patterns of human TAARs
One of the major challenges in the TAAR field is the generally low receptor expression levels, at least under basal conditions, which necessitates the use of the most stringent of reagents and methodologies in order to prevent cross-reactivity. Indeed, cursory searches of publicly available databases indicate sparse gene or protein expression in most human tissues including brain. RNA-seq databases in particular fail to show significant presence of TAARs. TAAR transcripts have, however, usually been demonstrated by quantitative PCR, suggesting unusually low mRNA levels. As with many other GPCRs (Michel, Wieland, & Tsujimoto, 2009) , unequivocal demonstration of human TAAR protein expression has been hampered by the lack of commercially available, selective, antibodies for individual human receptors, and those that are commercially available have generally been disappointing in terms of both sensitivity and specificity (Shahid et al., unpublished data) . This has been a serious obstacle with independent verification of TAAR protein expression profiles often difficult to come by, and reported results subject to undue influence of differences in experimental protocols and reagents between groups. Given these concerns, currently mRNA based tissue expression profiles are perhaps more reliable, but come with the caveat that they do not provide definitive evidence for the presence of the corresponding protein transcripts. The availability of high quality, truly selective antibodies, suitable for cellular and subcellular analysis of human samples remains a major requirement for the advancement of the TAAR field, in terms of both pharmacology and identifying potential therapeutic applications. Recently two excellent antibodies have been developed at Hoffmann-La Roche, an antihuman TAAR1 antibody that works well for immunohistochemistry of peripheral tissue (Raab et al., 2016) , and an anti-rat TAAR1 antibody that is suitable for Western blot analysis (Harmeier et al., 2015) . Notwithstanding the above limitations, with the exception of TAAR1, all TAARs appear to be expressed in the olfactory epithelium of all vertebrate species studied (Gliem, Schild, & Manzini, 2009; Hashiguchi & Nishida, 2007; Horowitz, Saraiva, Kuang, Yoon, & Buck, 2014; Kanageswaran et al., 2015; Liberles & Buck, 2006; Syed et al., 2015) , including humans (Carnicelli, Santoro, Sellari-Franceschini, Berrettini, & Zucchi, 2010) with the possible exception of bottle-nosed dolphin (Eyun et al., 2016) . Here TAARs are involved in the detection of olfactory cues of diverse ecological and ethological origins, and the initiation of innate behavioural responses (Dewan, Pacifico, Zhan, Rinberg, & Bozza, 2013; Ferrero et al., 2011; Li et al., 2013; Liberles, 2015; Zhang et al., 2013) . In addition, however, TAARs also appear to be expressed throughout the body, although further validation of such distributions is required.
2.1.1.1. TAAR1. Unfortunately insufficient data exists so far with respect to the human central nervous system expression of TAAR1. The most reliable expression data comes from studies using Taar1 knock-out mice, in which the entire Taar1 coding sequence was replaced by a reporter gene consisting of LacZ fused to a nuclear localization sequence. In the targeted allele, LacZ was expressed from the endogenous Taar1 promoter, thus providing a sensitive means for the study of TAAR1 tissue distribution (Lindemann et al., 2008) . In general TAAR1 appears to be heterogeneously distributed throughout the central nervous system, with mRNA and protein generally localized to monoaminergic nuclei and their projection fields including ventral tegmental area (VTA), substantia nigra pars compacta (SNpc), raphe nuclei, limbic areas, amygdala, prefrontal cortex, and basal ganglia (Figure 1 ), as well as in spinal cord in multiple species including human (Borowsky et al., 2001; Gozal et al., 2014; Lindemann et al., 2008) . In addition, human TAAR1 expression has also been suggested in astrocytes (Cisneros & Ghorpade, 2014) . The expression of TAAR1 in areas where dopaminergic (VTA, SNpc), serotonergic (dorsal raphe, VTA), and glutamatergic (cortex, amygdala, subiculum) neurones originate makes it ideally positioned to modulate and regulate reward circuits, the limbic network, cognitive processes, and mood states (Figure 1 ), making it an attractive drug target for a variety disorders, in particular schizophrenia, bipolar disorder, addiction, drug abuse, and Parkinson's disease.
Although the low expression levels and lack of good quality antibodies have prevented definitive ultrastructural studies, there is good evidence of both pre- (Bradaia et al., 2009; Leo et al., 2014; Revel et al., 2011) and post-synaptic (Espinoza, Ghisi et al., 2015) TAAR1 mediated effects in animals. While the expressed protein remains largely intracellular (Bunzow et al., 2001; Miller et al., 2005) , possibly due to an absence of N-terminal glycosylation sites (Barak et al., 2008) , plasma membrane expression is promoted following agonist-induced heterodimerization of TAAR1 with other GPCRs (Espinoza et al., 2011; Harmeier et al., 2015) .
Outside of the CNS, TAAR1 is mainly expressed in pancreatic β-cells, stomach and intestines in human, rat and mouse (Adriaenssens et al., 2015; Chiellini et al., 2012; Ito et al., 2009; Kidd et al., 2008; Raab et al., 2016; Regard, Sato, & Coughlin, 2008; Revel et al., 2013) (Figure 2 ). As observed in CNS neurones, TAAR1 in these non-neuronal cells also appears to be primarily intracellular (Raab et al., 2016) . In addition, several groups have reported TAAR1 expression in both human and mouse leukocytes (Babusyte et al., 2013; D'Andrea et al., 2003; Nelson, Tolbert, Singh, & Bost, 2007; Wasik, Millan, Scanlan, Barnes, & Gordon, 2012) , with expression reported to be increased following leukocyte activation Wasik et al., 2012) . While initial studies suggested expression was also present in the liver, kidney, lung (Borowsky et al., 2001 ) and testis (Chiellini et al., 2012) , more recent studies with better characterized, specific anti-human TAAR1 antibodies, as well as using Taar1 knock-out/LacZ knock-in mice, have failed to confirm this (Raab et al., 2016; Revel et al., 2013) . Very recently, TAAR1 expression has also been reported in human breast cancer tissue with expression levels reported to be correlated with survival rates (Vattai et al., 2017) . As described above, however, the commercial anti-TAAR1 antibody used in these studies is far from optimal, and caution is required in interpretion until studies have been replicated with fully validated, highly selective antibodies.
2.1.1.2. Other TAARs (2, 5, 6, 8, 9) . Very few studies have examined the tissue distribution patterns of TAARs other than TAAR1 in any species, and attempts to replicate these few studies have rarely occurred. This is a major knowledge gap in the field that desperately needs to be filled in order to stimulate further progress. In the absence of known endogenous ligands, however, there is low motivation for such studies both at the researcher and granting agency level, presenting an uncomfortable stalemate where the knowledge gap itself acts as a roadblock to the studies necessary to advance the field.
Outside of the olfactory system, TAAR2 mRNA has been identified in various cells of the gastrointestinal system in mice, with a preferential localization to duodenal mucosal cells (Ito et al., 2009) . TAAR2 mRNA transcripts have also been reported in rat heart (Chiellini et al., 2007) and testis (Chiellini et al., 2012) . In humans TAAR2 expression in leukocyte populations mirrors that of TAAR1, with mRNA identified in B-cells, granulocytes, monocytes, NK-cells, and T-cells (Babusyte et al., 2013; Nelson et al., 2007) , and protein confirmed in granulocytes (Babusyte et al., 2013) , although data confirming the selectivity of the antibodies used was not provided. A sub-population of granulocytes co-express TAAR1 and TAAR2, with evidence for heterodimerization of the two reported (Babusyte et al., 2013) .
Expression of TAAR5 mRNA in the mouse brain has been reported in the amygdala, arcuate nucleus, and ventromedial hypothalamus (Dinter, Muhlhaus, Wienchol et al., 2015) , with expression overlapping with that of TAAR1 in the amygdala and hypothalamus. Low level mRNA expression has also been reported in the rat spinal cord (Gozal et al., 2014) and testis (Chiellini et al., 2012) . Regulated TAAR5 expression has also been reported in rat intestines (Kubo et al., 2015) . In humans, low abundance TAAR5 mRNA has been identified in various leukocyte populations, with a somewhat greater expression in B-cells (Babusyte et al., 2013) , although others failed to identify TAAR5 in any human leukocyte population . Whether the mRNA is translated to functional protein in any of these cell types, however, has not been examined. Given that a putative endogenous ligand for TAAR5 has been identified (see Section 2.2.3) it is a little surprising that more attention has not been focused on its expression outside of the olfactory system. Similar to TAAR2, TAAR6 mRNA is also reported to be preferentially expressed in mouse duodenal mucosal cells (Ito et al., 2009) , rat (Gozal et al., 2014) but not human (Duan et al., 2004) spinal cord, and rat testis (Chiellini et al., 2012) . In humans TAAR6 transcripts have been reported throughout the brain, including amygdala (Borowsky et al., 2001; Duan et al., 2004) , basal ganglia (Duan et al., 2004) , frontal cortex (Duan et al., 2004) , hippocampus (Borowsky et al., 2001; Duan et al., 2004) and substantia nigra (Duan et al., 2004) . Indeed the expression of TAAR6 may be considerably more abundant in many brain regions than the more widely studied TAAR1 (Duan et al., 2004) . In addition, TAAR6 transcripts have been reported in human kidney (Borowsky et al., 2001 ) and in various human leukocyte populations (Babusyte et al., 2013; D'Andrea et al., 2003) .
The presence of TAAR8 mRNA has been observed in human amygdala (Borowsky et al., 2001 ) and rat spinal cord (Gozal et al., 2014) . Although only one TAAR8 isoform is present in humans, some species have additional variants. TAAR8a mRNA expression was reported in rat cortex and cerebellum (Chiellini et al., 2012) , although levels of the Fig. 1 . Based on animal studies TAAR1 is hypothesized to be expressed in key brain areas for the modulation of dopaminergic, serotonergic, and glutamatergic functions that regulate reward circuits, the limbic network, cognitive processes and mood states. Fig. 2 . TAAR1 activation affects food intake, controls glucose, and reduces weight through insulin increases and incretin-like effects on gastrointestinal hormonal release. TAAR1 expression in the periphery is indicated with "x".
TAAR8b isoform were barely above the limits of detection in various mouse brain regions (Muhlhaus et al., 2014) . TAAR8 mRNA has been reported to be increased in response to lipopolysaccharide activation of astroglia (D'Andrea et al., 2012) , suggesting a functional relevance. Outside of the CNS, TAAR8 mRNA has been identified in human (D'Andrea et al., 2003) and mouse leukocytes, although Babusyte and colleagues failed to confirm the presence of TAAR8 in any of their leukocyte populations (Babusyte et al., 2013) . Heart (Chiellini et al., 2012) , intestines (Chiellini et al., 2012) , kidney (Borowsky et al., 2001; Chiellini et al., 2012) , lung, muscle, spleen, stomach, and testis (Chiellini et al., 2012) have all also been reported to contain TAAR8 mRNA species in mouse (Chiellini et al., 2012) , rat (Chiellini et al., 2012) , and human (Borowsky et al., 2001) .
Much like other TAARs, TAAR9 mRNA has been identified in the mouse gastrointestinal tract, again preferentially localized to duodenal mucosal cells (Ito et al., 2009) , rat spinal cord (Gozal et al., 2014) , and in the full range of human leukocytes (Babusyte et al., 2013; D'Andrea et al., 2003) . Expression has also been reported in the spleen (Regard et al., 2008) . In humans expression was also suggested to be present in the pituitary gland and skeletal muscle (Vanti et al., 2003) .
Subcellular distribution of human TAARs
There is currently very little detailed information on the subcellular localization of TAARs in any species. This is perhaps not surprising given the lack of good quality tools, such as selective antibodies and radioligands, suitable for detailed studies of the subcellular compartmentalisation of the receptors. Most of the available data relates to TAAR1, and although the issue is not fully resolved, it is generally accepted that TAAR1 resides primarily intracellular (Grandy, Miller, & Li, 2016; Jing & Li, 2015; , possibly associated with as yet unidentified membrane components (Xie, Vallender et al., 2008) , but may translocate to the plasma membrane following receptor heterodimerization (Espinoza et al., 2011; Harmeier et al., 2015) . Certainly expression of human TAAR1 in standard mammalian expression systems leads to poor receptor presence at the plasma membrane (Barak et al., 2008; Grandy, 2007; , possibly due to the aforementioned absence of N-terminal glycosylation sites (Barak et al., 2008) . Indeed, various chimaeric receptors have been developed in order to increase TAAR1 plasma membrane expression and facilitate the examination of TAAR1 pharmacology with industry standard screening technologies (Barak et al., 2008; Hu et al., 2009; Reese, Bunzow, Arttamangkul, Sonders, & Grandy, 2007) . It is worth noting in this regard that other GPCRs, in particular those involved in olfaction, show similarly poor plasma membrane insertion in standard expression systems (Saito, Kubota, Roberts, Chi, & Matsunami, 2004; Zhuang & Matsunami, 2007) and at least some of these are also expressed outside of the olfactory system, including in the central nervous system (Ferrer et al., 2016; Kang & Koo, 2012) .
Human TAAR signal transduction
By virtue of it being the only human variant with clearly established endogenous ligands and the best characterized tissue distribution, the vast majority of attention has focussed on determining the pharmacology and physiology of TAAR1, with very little known about the signal transduction events at other human TAARs. This lack of basic pharmacological and physiological characterization of individual TAARs is again a major gap in the field that needs to be addressed. The main exception to this is in the olfactory system where all expressed TAARs appear to be co-expressed with G olf and coupled to cAMP accumulation (Liberles & Buck, 2006) , as would be expected of receptors involved in olfaction.
2.1.3.1. TAAR1. TAAR1 is coupled to the G s -protein (Borowsky et al., 2001; Bunzow et al., 2001) , and in addition to stimulating cAMP production, also recruits the G protein independent β-arrestin 2 cascade (Espinoza, Ghisi et al., 2015; Harmeier et al., 2015) . TAAR1 has also been reported to tonically increase the opening of inwardly rectifying K + -channels that have the characteristics of GirK channels (Bradaia et al., 2009; Revel et al., 2011) . Consistent with its CNS distribution, TAAR1 appears to function as an endogenous rheostat, regulating the efficacy of receptor activation in other neurotransmitter systems. Particularly well studied is the interaction of TAAR1 with dopaminergic systems, where activation of TAAR1 prevents dopaminergic hyperactivity (Bradaia et al., 2009; Revel et al., 2011; Revel et al., 2013) . Such effects appear to be due to a regulation of D2-like dopamine receptors (Bradaia et al., 2009; Espinoza, Ghisi et al., 2015; Wolinsky et al., 2007) as a result of TAAR1-D2 heterodimerization (Espinoza et al., 2011; Salahpour et al., 2012) in the presence of TAAR1 agonists (Harmeier et al., 2015) . Again this effect occurs both pre- (Harmeier et al., 2015) and post- (Espinoza, Ghisi et al., 2015) synaptically and appears to induce biased agonism, with signaling via the β-arrestin 2 pathway being promoted by the heterodimerization (Espinoza, Ghisi et al., 2015; Harmeier et al., 2015) . Biased signaling is an area that is receiving increasing attention for the development of pharmacotherapies, and the ability of TAAR1 to act as an endogenous system to bring about biased outputs is expected to generate considerable future interest.
There is considerable complexity and reciprocal interactions occurring during TAAR1-mediated regulation of dopaminergic activity, and this considerably complicates interpretation. In addition to TAAR1 regulating both pre-and post-synaptic D2-like receptors, D2-like receptor activation also regulates TAAR1 signalling (Espinoza et al., 2011; Harmeier et al., 2015) . Further, there is good evidence that TAAR1 is either constitutively active, or tonically activated by endogenous agonists (Bradaia et al., 2009) , consistent with both the lack of vesicular storage (Dyck, 1989; Henry, Russell, Clemens, & Plebus, 1988 ) and non-exocytotic release (Berry, Hart, Pryor, Hunter, & Gardiner, 2016; Berry, Shitut, Almousa, Alcorn, & Tomberli, 2013) of the endogenous agonist p-tyramine. In this respect dopamine receptor induced regulation of the synthesis of endogenous TAAR1 agonists (Berry, 2004; Juorio, Greenshaw, Zhu, & Paterson, 1991) adds a further level of reciprocal cross-talk. Regulation of the plasma membrane dopamine transporter (DAT) by TAAR1 is also possible Xie, Westmoreland, & Miller, 2008; Xie et al., 2007) , although TAAR1 agonists do retain activity in mice lacking DAT (Revel et al., 2011; Revel, Moreau et al., 2012) . The overall effect of this cross-talk is that very different outputs from TAAR1-D2 interactions may occur at pre-and postsynaptic sites. Nonetheless, the net effect at the circuit level is of TAAR1 acting to prevent hyperactivity of the dopaminergic system (Revel et al., 2011) .
Regulation of other neurotransmitter systems by TAAR1 has also been reported, in particular TAAR1-mediated regulation of pre-synaptic 5HT 1A receptors (Revel et al., 2011) . Similar to the situation seen with D2-like receptors, heterodimerization of human TAAR1 and α 2a -adrenoceptors has been observed, an interaction which appears to decouple the adrenergic receptors from their usual G i signaling pathway (Dinter, Muhlhaus, Jacobi et al., 2015) . Whether this is associated with a switch to signaling via the β-arrestin pathway, as is seen following heterodimerization with D2-like receptors, remains to be determined. A TAAR1-mediated regulation of NMDA receptor sub-units has also been reported, an effect that increases the magnitude of excitatory post-synaptic potentials (Espinoza, Lignani et al., 2015) . TAAR1 activation can also overcome NMDA receptor blockade (Revel et al., 2011) , consistent with TAAR1-mediated enhancement of glutamatergic transmission. As such, TAAR1 activation can act to prevent dopaminergic hyperactivity while simultaneously overcoming hypoactivity of the glutamatergic system, a spectrum of activity particularly relevant to the pharmacotherapy of schizophrenia (see Section 3.1). (2, 5, 6, 8, 9) . As previously indicated, all TAARs within the olfactory epithelium are coupled to G olf to regulate cAMP accumulation (Liberles & Buck, 2006) . Co-immunoprecipitation experiments suggest that, at least in neutrophils, TAAR2 can heterodimerize with TAAR1 (Babusyte et al., 2013) . This effect appears to be physiologically significant, as siRNA knock-down of either TAAR1 or TAAR2 prevents the chemotactic response of neutrophils to 2-phenylethylamine (Babusyte et al., 2013) . Since 2-phenylethylamine is not a ligand for TAAR2, it suggests that a functional interaction between TAAR1 and TAAR2 is required for the chemotactic response. Interestingly, this chemotactic response has separately been reported to be dependent on G i signaling (Malki et al., 2015) , and whether this represents the TAAR2 component or a heterodimerization-induced switch in TAAR1 signaling requires further study.
Other human TAARs
Human TAAR5 has been reported to be coupled to the G s cascade (Wallrabenstein et al., 2013) , the G q/11 cascade (Dinter, Muhlhaus, Wienchol et al., 2015) and G 12/13 dependent MAP kinase pathways (Dinter et al., 2015) . In contrast TAAR8 is reported to be coupled to G i (Muhlhaus et al., 2014) . Whether some of the variability in coupling observed for individual TAARs represents heteromer-, ligand-, or cell-dependent coupling of the receptors, as is the case with D1 dopamine receptors (Beaulieu & Gainetdinov, 2011) , still requires further clarification. The signal transduction events linked to TAAR6 and TAAR9 are still unknown.
Human TAAR ligands
The cognate ligands at the majority of TAARs remain unknown (Tables 1 and 2 ) and currently only one of the family members, TAAR1, is officially deorphanized by IUPHAR (Alexander et al., 2015; Maguire et al., 2009) . This is in part a function of the low endogenous expression levels and predominantly intracellular location of TAARs, which has hampered the use of industry-standard automated screening protocols for the identification of ligands. The identification of TAARs as a novel family of receptors for olfaction has, however, led to the identification of some endogenous compounds ( Table 2 ) that appear to selectively activate individual TAAR (Ferrero et al., 2012) . Whether any of these are indeed the true ligands, induce physiological responses in tissues other than the olfactory apparatus, or are ligands for a given TAAR sub-type in all species, remains unknown and requires systematic study. This does, however, provide an avenue through which the physiological role of family members other than TAAR1 can begin to be examined. For example, at least one rodent TAAR is activated by cadaverine, although which one has yet to be established (Hussain et al., 2013) , suggesting that the diamine family of compounds may be additional sources of TAAR ligands. Consistent with this a putative diamine binding domain has been identified in some TAARs, including human TAAR6 and TAAR8 .
A degree of caution is, however, required. In much the same way that there are pronounced species differences in TAAR expression profiles, evidence is accumulating that species differences in ligand selectivity may also occur. Differences in agonist potency between rodent and human TAAR1 are well established (Table 3) (Coster, Biebermann, Schoneberg, & Staubert, 2015; Reese et al., 2007; Simmler, Buchy, Chaboz, Hoener, & Liechti, 2016; Tan et al., 2009; Wainscott et al., 2007) and species differences in ligand selectivity towards TAAR5 may also be present (Staubert et al., 2010) . This necessitates that the activity of putative ligands be specifically verified with cloned human receptors.
TAAR1
TAAR1 is the only human variant that is activated by the archetypal trace amines 2-phenylethylamine, p-tyramine and tryptamine (Tables 1  and 3 ) (Borowsky et al., 2001; Bunzow et al., 2001) , and it is on this basis that the receptor family has been named. Although not a functional variant in humans, TAAR4 also responds to 2-phenylethylamine (Borowsky et al., 2001; Ferrero et al., 2011) and tryptamine (Borowsky et al., 2001) , which needs to be borne in mind for studies employing the endogenous ligands in rodent systems. A further complicating factor to the study of TAAR1 is its very broad ligand tuning. Not only are 2-phenylethylamine, p-tyramine and tryptamine full agonists, but it is also activated by an array of other endogenous compounds, all of which are primary amines (Table 3 ). This includes p-octopamine (Bunzow et al., 2001; , the endogenous thyroid hormone metabolite 3-iodothyronamine (Scanlan et al., 2004) , and the O-methyl metabolites of catecholamine neurotransmitters (Bunzow et al., 2001; Eff.: Efficacy, maximal cAMP levels reached compared to control. * Inverse agonist.
a Liberles & Buck (2006) . b Wallrabenstein et al. (2013) . c Li et al. (2015) . al., 2010). In addition, dopamine and 5-HT act as partial agonists (Bunzow et al., 2001; Wainscott et al., 2007) . As illustrated in Table 3 , a large array of psychoactive compounds and designer drugs also activate TAAR1 (Bunzow et al., 2001; Simmler et al., 2016) , among them amphetamine-like compounds including amphetamine itself, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"); phenethylamines like mescaline, 2,5-dimethoxy-4-bromophenethylamine (2C-B) and 2,5-dimethoxy-4-propyl-phenethylamine (2C-P); tryptamines such as psilocin and N,N-dimethyltryptamine (DMT); the ergoline lysergic acid diethylamide (LSD); piperazines like m-chlorophenylpiperazine (m-CPP); and aminoindanes including 2-aminoindane (2-AI) and 5-iodo-2-aminoindane (5-IAI). It is important to note, however, that (i) there is again substantial species differences with respect to potency, and several compounds that are active at rodent TAAR1 are inactive at human TAAR1, including mescaline, psilocin, DMT, LSD, m-CPP and methcathinone, and (ii) even where activity is observed, several compounds including MDMA, 2C-B, mescaline, m-CPP and LSD are partial agonists.
This spectrum of activity has raised interest in TAAR1 as a possible target for the pharmacotherapy of substance abuse and this is discussed more fully below (see Section 3.2). In contrast, neither cocaine (Bunzow et al., 2001; Simmler et al., 2013) , methylphenidate (Bunzow et al., Eff.: Efficacy, maximal cAMP levels reached compared to 10 μM 2-phenylethylamine a Simmler et al. (2016) . b . c Sotnikova et al. (2010) . d Sukhanov et al. (2014) . e Liu et al. (2014) . f Scanlan et al. (2004) . g Coster et al. (2015) . h Hu et al. (2009) . i Revel, Meyer et al. (2012) . k Revel et al. (2011) . l Revel, Moreau et al. (2012) . m Revel et al. (2013) . n Stalder et al. (2011). 2001; Simmler et al., 2016) , nor the majority of the cathinone class of psychotropics (Simmler, Rickli, Hoener, & Liechti, 2014; Simmler et al., 2016) interact with TAAR1. Apomorphine (Sukhanov et al., 2014) , ractopamine (Liu, Grandy, & Janowsky, 2014) , and, interestingly, various imidazoline-type 1 and type 2 receptor ligands such as clonidine, guanabenz and idazoxan (Hu et al., 2009 ) are amongst the vast array of synthetic compounds also reported to show agonistic activity at TAAR1, at least in some species (Table 3) . A dedicated TAAR program at Hoffmann-La Roche has generated a number of highly selective, synthetic TAAR1 agonists and partial agonists (Table 3) , based on different chemical skeletons (Edelmann et al., 2016; Galley, Stalder, Goergler, Hoener, & Norcross, 2012; Galley et al., 2016) . Phase I clinical studies with one of the lead compounds (RO5263397) from this program confirmed that TAAR1 is a viable target for pharmacotherapy, although identification of a human population of poor metabolizers of RO5263397 slowed further development (Fowler et al., 2015) . New partial agonists are now in development for psychiatric disorders.
In addition, other groups have described ligands based on 3-iodothyronamine (Chiellini et al., 2015) and a diphenylmethane scaffold (Chiellini et al., 2016 ) that possess nanomolar EC 50 values for mouse TAAR1 in functional assays. Homology modelling of human TAAR1 has also recently been developed (Cichero, Espinoza, Gainetdinov, Brasili, & Fossa, 2013) , and this has identified a variety of chemical scaffolds showing both agonist and antagonist activity (Cichero et al., 2014) , including a series of biguanide derivatives with nanomolar agonist potency at human TAAR1 (Tonelli, Espinoza, Gainetdinov, & Cichero, 2017) . The development of such in silico models has also begun to shed light on the atomic basis of both the broad ligand tuning (Kleinau et al., 2011 ) and species differences in ligand binding to TAAR1 (Reese et al., 2014; Tan et al., 2009) .
While a wide range of agonists have been identified, development of antagonists has proven problematic, with only a single antagonist compound (EPPTB) fully characterized in the literature (Bradaia et al., 2009; Stalder, Hoener, & Norcross, 2011) . EPPTB is now commercially available and a highly potent and selective mouse TAAR1 antagonist in vitro, although weaker and less selective in inhibiting rat and human TAAR1 (Table 3 ). In addition, unfortunately, its pharmacokinetic profile also limits its usefulness in vivo (Bradaia et al., 2009) . Further, whether EPPTB is a true antagonist, or rather an inverse agonist has been questioned (Bradaia et al., 2009; Stalder et al., 2011) . The lack of suitable antagonist compounds has been a major stumbling block for studying the basic pharmacology of TAAR1, forcing researchers to rely on gene knockdown approaches in lieu of antagonist studies. This has considerably slowed and complicated the elucidation of TAAR1-mediated effects, with compensatory mechanisms to chronic gene silencing of a constitutively active receptor difficult to control for. Just why TAAR1 appears inherently resistant to the development of antagonists and traditional medicinal chemistry approaches remains an open question. The development of in silico modelling is helping in this regard, and structures suitable for further investigation as selective antagonists have been described (Cichero et al., 2014; Tan, Groban, Jacobson, & Scanlan, 2008) , although at present do not appear to have been further characterized or developed. With a diversity of selective chemical backbones now identified, as well as putative receptor binding motifs, it is hoped that additional selective TAAR1 reagents, including brain permeable antagonists will soon become available. Further, additional candidates with suitable pharmacokinetic parameters for clinical development are anticipated.
TAAR2
Ligands for TAAR2 have not been described, although based on evolutionary mapping the available evidence suggests that the receptor will be tuned to one or more primary amines (Ferrero et al., 2012) . Recently the first application of a structure-based in silico computational protocol for the development of TAAR2 homology models was attempted . The use and further refinement of such models is expected to be a major benefit to the identification and development of TAAR2 selective ligands.
TAAR5
Consistent with studies of the evolutionary origin of TAAR that indicates TAAR5-9 isoforms are a distinct clade, these receptors all appear to be tuned primarily toward tertiary amines, in contrast to the primary amine tuning of TAAR1-4 (Tables 2 and 3) (Ferrero et al., 2012) . Trimethylamine is a potent and selective agonist at human TAAR5 (Liberles & Buck, 2006; Wallrabenstein et al., 2013; Zhang et al., 2013) , with dimethylethylamine a less potent partial agonist (Table 2 ) (Wallrabenstein et al., 2013) . In contrast, one report has suggested that while trimethylamine activated rodent TAAR5, it was without effect at primate, including human, variants (Staubert et al., 2010) . Such contradictory studies emphasize the need for a thorough, basic, pharmacological characterization of individual TAAR subtypes. At present it is difficult to discern whether such variability in results represents true species variations in ligand selectivity, are artefacts of the use of heterologous expressions systems, or a combination of the two. Such confusion is unlikely to be resolved until native cellular systems expressing individual TAARs are identified. Even then, the possible requirement for ligand binding or receptor dimerization in order to induce cell surface expression presents a considerable obstacle to traditional medicinal chemistry approaches.
Trimethylamine is produced primarily as part of choline and carnitine metabolism in the gastrointestinal tract by both commensal and non-commensal microbiota (Fennema, Phillips, & Shephard, 2016; Zhang & Davies, 2016) , although other more minor sources are also possible. Under normal circumstances trimethylamine is rapidly metabolized by flavin containing monooxygenase 3 (FMO3; E.C. 1.14.13.148) in the liver, and a genetic deficit in this enzyme leads to the accumulation of trimethylamine associated with trimethylaminuria, more commonly known as fish (mal)odour syndrome. In addition, FMO3 polymorphisms that increase the metabolism of trimethylamine are known to also occur (Robinson-Cohen et al., 2016) . The activity of FMO3 is altered during oestrus (Zhang, Mitchell, & Smith 1996; Shimizu, Cashman, & Yamazaki, 2007) and pregnancy (Hukkanen, Dempsey, Jacob III, & Benowitz, 2005) , suggesting regulation by female sex hormones, although the physiological relevance of this is unknown. Trimethylaminuria itself is rather benign, with no pronounced physiological symptoms beyond the socially unpleasant fish odour associated with the accumulation and excretion of excessive trimethylamine in bodily secretions and exhaled air. The product of FMO3 action, trimethylamine-N-oxide has become increasingly implicated in human health, with links to cardiovascular disease, reverse cholesterol transport and regulation of glucose and lipid metabolism (Fennema et al., 2016; Zhang & Davies, 2016) . Whether altered TAAR5 signalling contributes to such disease indications is unknown, although trimethylamine-N-oxide can also be converted back to trimethylamine by members of the constitutive microbiota (Fennema et al., 2016) . The potential relevance of microbiota produced TAAR ligands is discussed further in Section 4. Surprisingly, the TAAR1 agonist 3-iodothyronamine has been reported to be an inverse agonist at TAAR5 (Dinter, Muhlhaus, Wienchol et al., 2015) . Docking studies using both human and mouse TAAR5 homology models have confirmed 3-iodothyronamine, trimethylamine and dimethylethylamine binding to TAAR5 (Cichero et al., 2016) , and expanded on this to identify two TAAR5 antagonists. The synthetic chemical Timberol® has also been suggested to be a TAAR5 antagonist (Wallrabenstein, Singer, Panten, Hatt, & Gisselmann, 2015) . At present, none of these antagonists have been used to investigate the role of TAAR5 outside of the olfactory system, and this is an area for future development. A protocol for the production of milligram quantities of modified human TAAR5 has also been described (Wang, Corin, Rich, & Zhang, 2011) , providing an additional avenue for structural and functional studies that may aid in the development of selective ligands and antibodies.
TAAR6
Similar to the situation with TAAR2, there are no known ligands for TAAR6 at present. Based on the described evolutionary relationships of TAARs, it is expected that TAAR6 might be tuned toward tertiary amines (Ferrero et al., 2012) . A putative diamine binding domain has been identified in human TAAR6 raising the possibility that diamines may also be ligands.
TAAR8 and TAAR9
Isoforms of rat TAAR8 and TAAR9 have been reported to be activated by carnivore urine (Ferrero et al., 2011) although the individual component(s) responsible for this activation is unknown. Activation of rat TAAR8c and TAAR9 by N-methylpiperidine and N,N-dimethylcyclohexylamine has also been reported (Table 2 ) (Ferrero et al., 2012; Liberles & Buck, 2006) . Similar to TAAR6, human TAAR8 contains a putative diamine binding domain .
Therapeutic implications and pre-clinical testing
Trace amines have long been implicated in neuropsychiatric disorders and extensive tables of changes in endogenous trace amine levels in various disease states have been published (Davis, 1989) . The identification of the TAAR family has allowed these putative relationships to be refined, strengthened, and based on animal research hypotheses about the potential therapeutic utility of TAAR-directed ligands developed for a wide range of indications within both the CNS and metabolic disease categories.
TAAR1 partial agonists in schizophrenia
The identification of TAARs immediately suggested a potential role in schizophrenia. The TAAR gene locus located at chromosome 6q23.2 overlaps with the established SCZD5 schizophrenia susceptibility locus (Cao et al., 1997; Kaufmann et al., 1998; Levinson et al., 2000) and function modifying TAAR1 variants have recently been linked to schizophrenia (John et al., 2017) . Further, TAAR1 is activated by various amphetamine-derived psychotropic agents that are known to precipitate psychotic episodes in susceptible individuals. Subsequent studies have shown that TAAR1 partial agonism is a particularly promising approach towards addressing some of the major neural circuitry changes thought to underlie much of the pathology associated with schizophrenia, namely mid-brain dopaminergic hyperactivity and cortical glutamatergic hypoactivity.
Decreasing TAAR1 function, either through administration of an antagonist or through selective gene knock-down induces a hyper-dopaminergic phenotype seen as an increase in the basal firing rate of dopaminergic neurones (Bradaia et al., 2009; Lindemann et al., 2008; Revel et al., 2011) , with the expected increase in dopamine release and metabolite levels at the level of the terminals . Further, in the absence of TAAR1 signalling, a pronounced increase in sensitivity to a wide variety of dopaminergic stimuli is seen (Espinoza, Ghisi et al., 2015) . In contrast, selective TAAR1 agonists decrease mesolimbic dopaminergic neurone firing (Bradaia et al., 2009; Lindemann et al., 2008; Revel et al., 2011) , again with the expected corresponding changes occurring on dopamine release in the nucleus accumbens Revel, Meyer et al., 2012) . Similar effects have been demonstrated in vivo, with TAAR1 agonists preventing the behavioural hyperactivity associated with either DAT knock-out or DAT inhibition by cocaine (Revel et al., 2011; Revel et al., 2013) . TAAR1 knock-out increases striatal D2-like dopamine receptor numbers (Espinoza, Ghisi et al., 2015) , the fraction of D2-like receptors in the high affinity state (Wolinsky et al., 2007) , and correspondingly D2-like receptor agonist potency (Bradaia et al., 2009) . As described earlier (see Section 2.1.3.1) the regulation of D2-like receptor function is now thought to occur following agonist-induced heterodimerization of TAAR1 with D2-like receptors, inducing a biased signalling via the β-arrestin 2/glycogen synthase kinase 3β cascade (Harmeier et al., 2015) at both pre- (Bradaia et al., 2009 ) and post- (Espinoza, Ghisi et al., 2015) synaptic locations.
Taken together, the above animal studies suggest that TAAR1 tonically acts to prevent dopaminergic hyperactivity and that TAAR1 agonism is a novel way to prevent over-activity mediated by D2-like receptors. As such TAAR1 agonism may present an alternative to classical neuroleptic treatments. Importantly, selective TAAR1 agonists are devoid of the side-effects that limit the efficacy of neuroleptics, with no evidence of extra-pyramidal side effects (Revel et al., 2013) . Indeed, TAAR1 partial agonists appear to uniquely prevent the side-effects associated with first-line anti-psychotics; preventing haloperidol-induced catalepsy and olanzapine-induced weight gain (Revel et al., 2013) . The prevention of haloperidol-induced catalepsy requires TAAR1, as TAAR1 knock-out also reduces haloperidol-induced catalepsy (Espinoza et al., 2011) . Haloperidol treatment is known to increase the synthesis of the endogenous TAAR1 agonists 2-phenylethylamine (Juorio et al., 1991; Zhu, Juorio, Paterson, & Boulton, 1993; Zhu, Juorio, Paterson, & Boulton, 1994) , 3-methoxytyramine and normetanephrine (Carlsson & Lindqvist, 1963) , an effect that can reasonably be expected to elevate constitutive TAAR1 signalling, and induce heterodimerization with D2-like dopamine receptors. In such a scenario it is envisioned that dysregulated TAAR1 signalling underlies the side-effects. As such partial agonists which can both promote TAAR1 signalling, while also decreasing elevated constitutive receptor activity is a particularly promising approach.
While classical antipsychotics are effective in controlling the positive symptoms of schizophrenia, they have limited benefit in treating higher cognitive deficits and negative symptomatology (Citrome, 2014; Miyamoto, Miyake, Jarskog, Fleischhacker, & Lieberman, 2012) . These symptoms are thought to be due to a combination of hypodopaminergic and hypoglutamatergic states in the prefrontal cortex. Atypical antipsychotics such as olanzapine can provide some moderate benefit in these areas. Using phMRI TAAR1 agonists were shown to give a greater enhancement of prefrontal cortical activity than does olanzapine (Revel et al., 2013) , suggesting the possibility of efficacy against a broader range of symptoms, including negative symptoms. Consistent with this, cognitive enhancement is seen in response to TAAR1 agonism in both primates and rodents (Revel et al., 2013) , although further evaluation is necessary in models of schizophrenia-related cognitive dysfunction (Elsworth et al., 2012) . Further, in addition to regulation of the dopaminergic system, TAAR1 also appears to regulate glutamatergic activity. TAAR1 deletion in mice causes effects consistent with decreased NMDA and increased AMPA receptor functioning (Espinoza, Lignani et al., 2015) . This was seen as decreases in both total and phosphorylated forms of the NMDA GluN1 sub-unit, as well as total GluN2B in the cortex, with a decrease in the total NMDA/AMPA receptor ratio. Behaviourally this was seen as increased impulsivity and perseverative responses (Espinoza, Lignani et al., 2015) . Such effects are thought to be cognitive traits associated with schizophrenia, and in wild-type mice selective TAAR1 agonists reduce this behaviour. Further, TAAR1 agonists also prevent the hyperlocomotor responses and cognitive deficits induced by NMDA receptor blockade (Revel et al., 2011; Revel et al., 2013) . As such, the available evidence suggests that in addition to preventing hyperdopaminergic states, TAAR1 also acts to prevent hypoglutamatergic states, and causes an increase in prefrontal cortical activity. Intriguingly, D2-like dopamine receptor partial agonists that are biased towards the β-arrestin pathway have been reported to show a similar normalization of hypoglutamatergic states (Park et al., 2015) , consistent with TAAR1 functions being mediated due to promotion of biased agonism following heterodimerization with D2-like receptors. A TAAR1 mediated regulation of the glutamate excitatory amino acid transporter 2 (EAAT2) has also been reported (Cisneros & Ghorpade, 2014) and this may contribute to the effects observed.
While it is generally viewed that 2-phenylethylamine and p-tyramine synthesis occurs in monoaminergic neurones, dedicated trace aminergic neurones may also be present. The so-called D-neurones are a group of cells that are present in both rodent and human brain and while containing aromatic L-amino acid decarboxylase, do not contain either the tyrosine hydroxylase enzyme required for dopamine and noradrenaline synthesis, nor 5HT (Jaeger et al., 1983; Jaeger et al., 1984; Kitahama et al., 2009 ). Such cells appear, at least on the surface, ideally suited to the synthesis of the TAAR1 ligands 2-phenylethylamine, p-tyramine and/or tryptamine. These cell groups, however, remain poorly studied, and their putative role as a trace aminergic system is far from established. It is worth noting though that decreases in D-neurone populations have been suggested to be present in post-mortem brains from patients with schizophrenia (Ikemoto, Nishimura, Oda, Nagatsu, & Nishi, 2003) .
Given the likely multi-factorial nature of schizophrenia, leading to a highly heterogenous patient population with multiple molecular aetiologies, the ability of TAAR1 to regulate the efficacy of multiple neurotransmitter systems, rather than directly bringing about signal transduction, is an attractive therapeutic modality. In this respect partial agonism, with the benefit of dual actions, antagonizing over-active constitutive activity while also normalizing hypo-functioning states is particularly attractive. Much effort has been devoted to treating schizophrenia by global alteration of classical neurotransmitter systems with only partial success. The TAAR1 system appears to provide a more subtle approach that taps into an apparent endogenous regulatory system to allow fine tuning of the synaptic efficacy of multiple neurotransmitter systems.
Clinical trials of TAAR1-directed compounds for schizophrenia are in progress. SEP-363856, a mixed 5HT 1A /TAAR1 agonist developed by Sunovion Pharmaceuticals was reported to show a good safety and tolerability profile in patients with schizophrenia, as well as improvements in positive and negative syndrome scale (PANSS) scores (Koblan et al., 2016) , and normalization of functional magnetic resonance imaging changes in various brain regions, consistent with a modulation of the dopaminergic reward circuitry (Nazimek et al., 2016) . These findings supported further clinical development of this compound.
Other TAARs in schizophrenia
While pre-clinical models have focussed on TAAR1 and provide compelling evidence for the likely utility of TAAR1 partial agonists in the clinic, there is minimal direct link between deficits in TAAR1 signalling and the aetiology of schizophrenia. A nonsense single nucleotide polymorphism in the TAAR2 gene was reported to have an increased prevalence in populations with schizophrenia (Bly, 2005) but this was based on a very small sample size and there are no known studies attempting to replicate the findings.
More studies have investigated a potential role of TAAR6 single nucleotide polymorphisms in schizophrenia aetiology, although results are far from conclusive. Initial studies suggested links in Korean (Pae, Drago et al., 2008; Pae, Yu et al., 2008) , European (Duan et al., 2004; Vladimirov et al., 2007) and African-American (Duan et al., 2004) pedigrees, although other studies failed to confirm associations in Japanese, Chinese and European populations (Duan et al., 2006; Ikeda et al., 2005; Ludewick et al., 2008; Sanders et al., 2008; Vladimirov et al., 2009) . Epistasis between TAAR6 and HSP-70 polymorphisms with respect to both the development of schizophrenia and treatment outcomes has also been suggested (Pae, Drago, Patkar, Jun, & Serretti, 2009) , as has a relationship between TAAR6 polymorphisms and response to aripiprazole (Serretti, Pae, Chiesa, Mandelli, & De Ronchi, 2009) . With a disease that shows such heterogeneity, lack of replication is not necessarily surprising, particularly when so many of the studies have relied on small sample sizes. This serves to highlight the need for a greater focus on understanding the basic physiological relevance of individual TAAR sub-types, in particular their distribution and endogenous ligands.
TAAR1 agonists as anti-craving agents
The initial pharmacological characterization of TAAR1 also suggested it as a potential novel target for the pharmacotherapy of substance abuse disorders (see . As described above, a number of psychotropic agents including amphetamine, methamphetamine, and MDMA are potent agonists at human TAAR1 (Bunzow et al., 2001; Simmler et al., 2016) . The subsequently observed regulatory effect of TAAR1 on dopaminergic systems has further strengthened this interest, given their well-documented involvement in reward circuitry.
Somewhat surprisingly given that amphetamine and methamphetamine are TAAR1 agonists, TAAR1 knock-out animals show increased sensitivity to both the hyperlocomotor effects of amphetamine and methamphetamine (Achat-Mendes, Lynch, Sullivan, Vallender, & Miller, 2012; Sukhanov et al., 2016) and reinstatement responses (Sukhanov et al., 2016) to these psychostimulants. Consistent with this, a defunctionalizing mutation of TAAR1 has been identified in the DBA/2J mouse strain that selects for high methamphetamine consumption (Harkness, Shi, Janowsky, & Phillips, 2015) . The basis of such effects appears to be that TAAR1 activation counteracts the psychomotor and pleasurable reinforcing components of psychostimulant action that are mediated through activation of dopaminergic neurotransmission (Harkness et al., 2015; . Consistent with this, a loss of auto-inhibitory effects had previously been reported in TAAR1 knock-out animals in response to another TAAR1-activating psychostimulant MDMA, along with increased MDMA-induced dopamine release (Di Cara et al., 2011) . Further, methamphetamine conditioned place preference (CPP) is acquired quicker, and retained longer in TAAR1 knock-out animals than in their wild-type littermates (Achat-Mendes et al., 2012) . In total, the effects of TAAR1 knock-out suggest that activation of TAAR1 may be an effective mechanism to decrease self-administration of psychostimulant compounds.
Selective TAAR1 agonists have now been confirmed to decrease methamphetamine self-administration, re-instatement, behavioural sensitization and motivation to seek methamphetamine (Cotter et al., 2015; Jing, Zhang, & Li, 2014; Pei, Asif-Malik, Hoener, & Canales, 2016) . Consistent with a distinction between TAAR1-and dopaminemediated effects, there was no effect of TAAR1 agonists on methamphetamine-induced dopamine release or inhibition of dopamine re-uptake (Cotter et al., 2015) . Similarly, although TAAR1 agonism prevented methamphetamine-induced dopamine overflow in the nucleus accumbens, dopaminergic neurotransmission was unaffected (Pei, Asif-Malik, Hoener, et al., 2016) . Such effects are consistent with TAAR1 activation causing regulation of D2-like dopamine receptor efficacy.
Recently it has become apparent that the effects of TAAR1 agonism may produce a general anti-craving phenotype, with similar effects reported even where the addictive agent does not directly interact with TAAR1. As such, similar to the results seen with amphetamine derivatives, TAAR1 agonists decrease cocaine-induced sensitization (Thorn, Zhang, Zhang, & Li, 2014; Thorn, Jing et al., 2014) and hyperactivity (Revel et al., 2011; Revel et al., 2013) . Importantly, cocaine-induced CPP (Thorn, Jing et al., 2014) , drug seeking behaviour following withdrawal (Pei et al., 2014) , both cue- (Thorn, Jing et al., 2014) and cocaine-primed (Pei et al., 2014; Thorn, Jing et al., 2014) reinstatement, propensity to self-administer (Pei, Mortas, Hoener, & Canales, 2015) , as well as reward memory (Liu, Thorn, Zhang, & Li, 2016) were all also prevented. Further, TAAR1 agonism decreases the rewarding efficacy of cocaine, as seen by a downward shift of dose-response curves . This decreased cocaine seeking behaviour in response to TAAR1 agonism appears to be associated with TAAR1 activation in the VTA, both core and shell of the nucleus accumbens, and the pre-limbic cortex (Liu, Siemian, Seaman, Zhang, & Li, 2017).
TAAR1 knock-out also increases voluntary ethanol consumption (Lynch et al., 2013) and it is interesting to note that the DBA/2J mouse strain reported to contain a defunctionalizing mutation in TAAR1 has previously been reported to show enhanced reward responses to both cocaine and ethanol as well (Fish et al., 2010) . Food addiction, manifest as compulsive binge eating, is also decreased in response to TAAR1 agonists (Ferragud et al., 2017) . Likewise, TAAR1 agonists also decrease nicotine self-administration, cue-and drug-induced behaviours .
All of the above addiction behaviors are thought to involve activation of the dopamine reward circuitry. In contrast drug seeking behaviors that are not thought to be dopaminergic in origin do not appear to be affected by regulation of TAAR1 activity. As such, morphine induced CPP is not affected by TAAR1 knock-out (Achat-Mendes et al., 2012) , and neither TAAR1 agonists (Cotter et al., 2015; Jing et al., 2014; Pei, Asif-Malik, Hoener, et al., 2016; Pei et al., 2014; Revel, Moreau et al., 2012) nor receptor knock-out (Lynch et al., 2013) affect either sucrose (Cotter et al., 2015; Jing et al., 2014; Lynch et al., 2013; Pei et al., 2014; Revel, Moreau et al., 2012) or chocolate-flavoured pellet (Pei, Asif-Malik, Hoener, et al., 2016) self-administration. These results suggest that TAAR1 agonism prevents drug-seeking behaviours through prevention of increased activity of the dopaminergic reward pathway. Importantly from a clinical perspective this is not due to a substitution phenomenon; TAAR1 agonists alone do not support self-administration (Cotter et al., 2015; Pei, Asif-Malik, Hoener, et al., 2016) . While the species differences in TAAR1 pharmacology can be a problem for translation to humans it is encouraging to note that the dopamine reward pathway was identified as a target of the mixed 5HT 1A /TAAR1 agonist SEP-363856 during phase I clinical trials (Nazimek et al., 2016) .
TAAR1 agonists as anti-depressants and stress-reducing agents
As with schizophrenia and substance abuse, putative links between trace amines and the aetiology of mood disorders far outdate the discovery of TAARs (Davis, 1989) , and the 6q23 TAAR gene locus also corresponds to a previously identified mood disorder susceptibility locus (Venken et al., 2005) . The regulation of adrenergic receptors (Dinter, Muhlhaus, Jacobi et al., 2015) , and both dopaminergic (Bradaia et al., 2009; Espinoza, Ghisi et al., 2015) and serotonergic (Revel et al., 2011) receptors and neuronal activity (Bradaia et al., 2009; Revel et al., 2011; Revel et al., 2013) by TAAR1, also suggests that TAAR1 agonists may be beneficial for the treatment of mood disorders. Indeed, both antidepressant-like and stress-reducing activity of TAAR1 agonists has been reported in animal models of depression and stress. In the rodent forced swim test TAAR1 partial agonists dose-dependently decrease immobility (Revel, Moreau et al., 2012; Revel et al., 2013 ) although a full agonist was without effect (Revel et al., 2013) . In contrast both full and partial agonists are effective in the primate differential reinforcement of lowrate behaviour assay (Revel, Moreau et al., 2012; Revel et al., 2013) . With respect to stress disorders, TAAR1 agonism has been reported to be beneficial in the stress-induced hyperthermia model (Revel et al., 2011; Revel, Moreau et al., 2012) , a model with good clinical predictive validity (Adriaan Bouwknecht, Olivier, & Paylor, 2007) . No effects of TAAR1 manipulation are observed in standard models of increased anxiety such as the elevated plus maze (Wolinsky et al., 2007) .
TAAR1 as a target in sleep disorders
During the initial characterization of selective TAAR1 partial agonists, a general wake-promoting effect was observed in rats (Revel, Moreau et al., 2012) , seen as a decreased latency to sleep, increased wakefulness and decreased NREM sleep over the 6 hours following administration at the mid-point of the dark (active) cycle. Spectral analysis further indicated that the NREM sleep that did occur was lighter (Revel, Moreau et al., 2012) . Similar results were also observed when dosing occurred during the light phase (Revel, Moreau et al., 2012; Revel et al., 2013) . Intriguingly, the TAAR1 full agonist RO5256390 had no effects on sleep under the same conditions (Revel et al., 2013) , raising the possibility that effects of the partial agonist were due to antagonism of endogenous TAAR1 tone. Subsequent studies confirmed similar effects of TAAR1 partial agonists in mice (Schwartz et al., 2017) , and using selective TAAR1 overexpression or knock-out also identified TAAR1 expression-dependent changes in sleep architecture and patterns that were due to a regulation of cortical activity (Schwartz et al., 2017) . Importantly, the wake promoting effects of TAAR1 partial agonists are not associated with hyperactivity (Revel et al., 2013; Schwartz et al., 2017) , unlike that seen with central stimulants such as caffeine. Surprisingly, although caffeine is not a ligand for TAAR1, its effects were exacerbated by TAAR1 over-expression, and attenuated by TAAR1 knock-out, as were the effects of modafinil (Schwartz, Palmerston, Lee, Hoener, & Kilduff, 2016) .
These studies indicate a role for TAAR1 in the normal homeostatic control of sleep, and suggest that TAAR1 ligands may be useful in sleep disorders such as narcolepsy. This has recently been confirmed in two mouse hypocretin neurone degeneration models of narcolepsy (Black, Schwartz, Chen, Hoener, & Kilduff, 2016) . Not only did this study confirm earlier reports indicating a role for TAAR1 in the control of sleep architecture, but it also showed beneficial effects of two TAAR1 partial agonists in both narcolepsy models. This was seen as a decrease in both hyperthermia and cataplexy, effects that were related to the strength of partial agonism (Black et al., 2016) . This again suggests that a brain permeable TAAR1 antagonist may be the preferred therapeutic entity. Unfortunately, as detailed earlier, TAAR1 has proven to be uniquely resistant to the development of antagonists, although it is hoped that this identification of a potential disease indication will further spur efforts toward their development.
TAAR1 agonists in metabolic disorders
Although fairly high levels of TAAR1 expression have been seen in the β-cells of the pancreas, the stomach and the intestines, the role of TAAR1 in peripheral tissues is far less studied. The first direct evidence for a role of TAAR1 in the control of energy metabolism came from the pre-clinical testing of TAAR1 ligands as novel therapeutics for schizophrenia, when the partial agonist RO5263397 was shown to prevent olanzapine-induced weight gain (Revel et al., 2013) . TAAR1 was confirmed to be present in the insulin-producing β-cells, but not the glucagon-producing α-cells of human pancreatic islets (Raab et al., 2016; Revel et al., 2013) . Selective TAAR1 agonism gives a dose-dependent enhancement of glucose-stimulated insulin secretion in both rat insulinoma cells and isolated human islets (Raab et al., 2016) . In vivo, acute selective TAAR1 activation lowers blood glucose excursion in response to an oral glucose challenge in C57BL/6, diabetic db/db, and diet-induced obese (DIO) mouse strains, effects that appear to be due to a delay in gastric emptying (Raab et al., 2016) . Importantly, while decreases in fasting glucose levels are seen in diabetic db/db and DIO mice, similar effects are not seen in wild-type controls. These studies build on earlier work with 3-iodothyronamine, which although a TAAR1 agonist also interacts with a number of other receptors and transporters (Hoefig, Zucchi, & Kohrle, 2016) making interpretation of results difficult. Administration of 3-iodothyronamine can cause both increases and decreases in insulin secretion, with the increases suggested to be TAAR1 mediated (Regard et al., 2007) .
As indicated above, not only is TAAR1 present in the pancreas but it is also found in the stomach (Adriaenssens et al., 2015; Raab et al., 2016) , and duodenum (Ito et al., 2009; Raab et al., 2016) , including in humans. In the duodenum TAAR1 is co-localized with glucagon-like peptide 1 (GLP-1) and peptide YY, with the glucose stimulated plasma levels of both being elevated following administration of a selective TAAR1 agonist (Raab et al., 2016) . In the stomach increased somatostatin secretion from D-cells following TAAR1 activation is observed (Adriaenssens et al., 2015) . As such, as summarized in Figure 2 , TAAR1 appears to also regulate hormone secretion related to the control of gastric function and nutrient absorption.
In vivo TAAR1 activation also decreases food intake following an overnight fast in C57BL/6 as well as in DIO mice (Raab et al., 2016) . Following sub-chronic dosing with a selective TAAR1 agonist, DIO mice show weight loss, improved insulin sensitivity, and decreased plasma and hepatic triglycerides (Raab et al., 2016) , effects that are consistent with the prevention of drug-induced weight gain (Revel et al., 2013) .
In total the available evidence suggests that TAAR1 agonism may be a novel therapeutic strategy for the treatment of type 2-diabetes and also shows potential for the pharmacotherapy of obesity from both drug-and diet-induced causes (Figure 2 ). While at least some of the effects described above almost certainly arise from local effects, a role for TAAR1 in the CNS control of energy metabolism and nutrient intake should also be considered. TAAR1 has been identified in brain areas associated with the regulation of nutrient intake, storage, and processing including the hypothalamus, limbic system and cortex. TAAR1 is also found in the area postrema and nucleus tractus solitarii (Figure 2) where it is ideally located to detect ligands present in the circulatory system, including those resulting from nutrient intake (see below). Further, the recent demonstration of the ability of TAAR1 agonists to prevent binge eating (Ferragud et al., 2017) appears to uniquely position such compounds to address both the centrally mediated over-consumption and subsequent insulin resistance and hormone imbalance aspects of obesity and associated metabolic disorders.
It is also important to note that ligands for TAAR1 may be exogenous in origin. The TAAR1 ligands 2-phenylethylamine and p-tyramine are found in a number of foods, in particular chocolate, red wine, aged cheeses, and fermented meats (Coutts, Baker, & Pasutto, 1986) . Further, these compounds, and putative ligands at other TAARs, are both readily produced by decarboxylation of dietary amino acids, and metabolized by the intestinal microbiota (Mazzoli & Pessione, 2016; Yang, Mu, Luo, & Zhu, 2015) . In these regards TAAR ligands should be considered with respect to the growing appreciation of the role of nutrients and the constitutive microbiota in regulating human health. Some of these aspects are explored in more detail in Section 4.
TAAR1 in Parkinson's disease
With such pronounced effects of TAAR1 on the control of central dopaminergic activity, a putative role in the control of Parkinson's disease symptomatology is an obvious possibility. Since TAAR1 agonists inhibit dopamine-dependent locomotor activity (Revel et al., 2011; Revel, Moreau et al., 2012; Revel et al., 2013; Sotnikova, Zorina, Ghisi, Caron, & Gainetdinov, 2008) it is reasonable to expect that TAAR1 blockade may potentiate locomotion. Indeed, haloperidol-induced catalepsy is significantly reduced in TAAR1 knock-out and heterozygous mice (Espinoza et al., 2011) and in response to TAAR1 partial agonist administration (Revel, Moreau et al., 2012) . Furthermore, DAT knock-out mice made fully dopamine deficient by inhibition of the rate-limiting dopamine synthetic enzyme tyrosine hydroxylase, when crossed with TAAR1 knock-out mice, demonstrate a striking increased efficacy of Ldopa in reversing akinesia and rigidity . Such results suggest that TAAR1 antagonists may be an effective adjunct therapy to L-dopa treatment.
With 2-phenylethylamine and p-tyramine synthesis via aromatic Lamino acid decarboxylase being under the control of dopamine receptor activation, an alteration of basal trace aminergic tone in L-dopa on-off symptoms has been hypothesized (Berry, 2007) . At the same time, the extracellular dopamine metabolite and TAAR1 agonist 3-methoxytyramine is increased during chronic L-dopa treatment and has been suggested to underlie L-dopa-induced dyskinesias, at least in part through an activation of TAAR1 (Sotnikova et al., 2010) . Although the complex locomotor behaviours induced by 3-methoxytyramine are partially alleviated in TAAR1 knock-out animals, similar dyskinetic-like or locomotor-promoting effects are not observed in response to acute administration of other TAAR1 agonists (Sotnikova et al., 2010) . Whether this represents a difference between chronic and acute elevations in TAAR1 signalling requires further study.
A more rapid sensitization to L-dopa treatment has also been observed in medial forebrain lesioned TAAR1 knock-out mice than in their wild-type litter-mates (Alvarsson et al., 2015) . This was seen as both a more rapid development and greater number of contralateral rotations, and involuntary movements in response to sub-chronic L-dopa/ benserazide administration. In contrast, L-dopa induced dyskinesias are prevented by the TAAR1 agonist RO5166017 in wild-type animals (Alvarsson et al., 2015) . The effects of TAAR1 manipulation correlated with changes in glutamatergic activity and post-synaptic AMPA receptor GluA1 phosphorylation; lesioned TAAR1 knock-out animals showing exacerbated phosphorylation whereas RO5166017 treatment of lesioned wild-type mice decreased phosphorylation, indicating increased and decreased glutamatergic activity respectively (Alvarsson et al., 2015) . The authors further suggested that these observed effects were downstream of TAAR1 modulation of D2-like dopamine receptor mediated control of cannabinoid receptor signalling, consistent with TAAR1-mediated effects seen in other experimental models.
In summary, evidence exists for the potential utility of both TAAR1 agonists and antagonists as adjunct therapies in Parkinson's disease and for the prevention of L-dopa induced-dyskinesias. The contradictory reports likely reflect the complex feedback regulation that exists between the trace amine and dopamine systems (a relationship which may vary as a function of lesion size), the use of different Parkinson's disease model systems, and differences between chronic and acute treatment responses. Notwithstanding the contradictory reports there is sufficient evidence to warrant a more thorough investigation of TAAR1 as a novel target for the control of Parkinson's disease symptomatology and L-dopa induced dyskinesias. Given the complex inter-relationships TAAR1 partial agonists may be particularly attractive, able to normalize both dopaminergic hyper-and hypoactive states which is likely particularly relevant in late-course Parkinson's disease where rapid fluctuation in symptom control occurs.
TAAR1 regulation of immune function
As described in earlier sections multiple groups have reported the presence of TAARs in human leukocyte populations (Babusyte et al., 2013; D'Andrea et al., 2003; Nelson et al., 2007; Sriram et al., 2016; Wasik et al., 2012) , with individual isoforms differentially expressed between different cell types (Babusyte et al., 2013) . That such expression is functionally relevant is suggested by an increase in TAAR1 and TAAR2 mRNA and protein (Wasik et al., 2012) in response to leukocyte stimulation. The TAAR1 ligands 2-phenylethylamine, p-tyramine and 3-iodothyronamine have been shown to act as chemoattractants for neutrophils, with sub-nanomolar EC 50 values, effects that require the presence of both TAAR1 and TAAR2 (Babusyte et al., 2013) . Such dependence on TAAR2, for which neither 2-phenylethylamine nor p-tyramine are ligands, is interesting, and may represent a requirement for heterodimerization between TAAR1 and TAAR2 to initiate neutrophil migration (Babusyte et al., 2013) . It is also interesting to note that both 2-phenylethylamine and p-tyramine were previously reported to be released from activated platelets (D'Andrea et al., 2003) , and as such TAAR1 activation may represent a previously unrecognized endogenous mechanism for the recruitment of leukocytes to the sites of injury.
Further supporting a functional role of trace aminergic systems in cellular immunity, TAAR1-mediated increases in interleukin-4 secretion from T-cells was detected in response to either 2-phenylethylamine, ptyramine or 3-iodothyronamine, while also decreasing the expression of secreted phosphoprotein 1 (Babusyte et al., 2013) . Such responses showed sub-nanomolar EC 50 values, which are consistent with a TAAR1-mediated promotion of T helper cell differentiation into the Th2 phenotype, which would favour subsequent B-cell activation.
Consistent with this interpretation, TAAR-mediated increases in immunoglobulin E secretion from B cells has been reported in response to 2-phenylethylamine and p-tyramine (Babusyte et al., 2013) . In contrast, TAAR1-mediated apoptosis of B cells has also been reported (Wasik et al., 2012) .
Immune dysfunction resulting in an increased sensitivity to infection has been associated with various drugs of abuse, in particular amphetamine and its derivatives (Boyle & Connor, 2010; Sriram, Haldar, Cenna, Gofman, & Potula, 2015) . Given that such compounds are agonists at TAAR1, and in light of the evidence for a role of TAAR1 in controlling immune cell activation, then TAAR1 may represent a molecular basis for such immune dysfunction. Indeed, methamphetamine has been reported to increase human T cell TAAR1 expression, and to decrease their interleukin 2 levels in a TAAR1-dependent manner (Sriram et al., 2016) . Such a TAAR1-dependent decrease in interleukin 2 levels is consistent with T cell differentiation being directed away from the Th1 phenotype, in accordance with the previously described promotion of the Th2 phenotype by TAAR1 agonists.
At this time it is too early to predict whether selective TAAR ligands will be of clinical utility in modifying immune cell function, and if so whether agonists or antagonists will be of most benefit. The above studies do, however, provide a framework for future studies to clarify the role of TAARs in immune function. Whether such immune system regulation is related to the apparent role of TAAR1 in fibromyalgia susceptibility (Smith et al., 2012) or TAAR6 in treatment outcomes in asthma (Chang et al., 2015) is an area for future study. Given the widespread presence of TAAR ligands and their precursors in foodstuffs, clarification of the role of TAARs in regulating immune function may also be of particular relevance to the identification of new therapeutic targets for food-induced inflammatory responses, such as in Crohn's disease, ulcerative colitis, and eosinophilic esophagitis.
Areas for future development

Definition of "trace amine" and identification of selective ligands
The lack of clearly defined endogenous ligands at the majority of TAARs, and indeed a consensus endogenous ligand for the family as a whole, has not only slowed progress in the field, but also hindered the acceptance of the putative relevance of the TAAR family by the wider scientific community. This has been exacerbated by the high rate of species-specific pseudogenization of individual isoforms that occurs, raising further questions about the functional relevance of individual TAAR isoforms. Indeed, it is widely reported that only one human family member, TAAR1, is activated by trace amines, and this was a major factor in the subsequent adoption of the term trace amine-associated for the receptor family. As previously described, the term trace amine, which has subsequently become synonymous with only a small group of compounds, was originally intended to represent a much broader range, namely any endogenous amines with tissue levels below 100 ng/g tissue. The available evidence indicates that all mammalian TAARs maintain a consensus amine-binding pocket (Eyun et al., 2016; Ferrero et al., 2012; Hussain et al., 2009) , and there is very little reason to suspect that the endogenous ligands at any mammalian TAAR are not aminergic. With trimethylamine (TAAR5) (Ferrero et al., 2012; Li et al., 2013; Wallrabenstein et al., 2013) and isoamylamine (TAAR3) (Ferrero et al., 2012; Saraiva et al., 2016; Zhang et al., 2013) accepted as endogenously produced compounds with selective agonistic activity at individual TAAR, we propose a return to the original definition, specifically that trace amines represent any endogenously produced amine with normal tissue levels below 100 ng/g tissue. Under such a definition, the family of trace amines would be expanded beyond p-tyramine, 2-phenylethylamine, tryptamine and p-octopamine to also include 3-iodothyronamine, trimethylamine, and isoamylamine. This may also be expanded to include members of the polyamine family, pan-TAAR knock-out prevents the avoidance behaviour shown towards cadaverine by wild-type mice (Dewan et al., 2013) . Furthermore, monoamine neurotransmitter metabolites such as 3-methoxytyramine that have long been regarded by the scientific mainstream as inactive extracellular metabolite markers are now established as TAAR1 agonists (Borowsky et al., 2001; Sotnikova et al., 2010) and should also be included as family members. Indeed this appears to represent an elegant evolutionary homeostatic mechanism whereby the metabolite that mirrors extracellular (synaptic) neurotransmitter levels acts at a separate receptor target to prevent over-activity of the neurotransmitter from which it was derived. It is also notable that many of the identified endogenous TAAR ligands are simply decarboxylated amino acids, and examining other decarboxylated forms of amino acids and their metabolites likely represents a good place to start the search for endogenous ligands at other TAARs. In this regard, and given the putative diamine binding motif suggested to be present in human TAAR6 and TAAR8 , agmatine may be of particular interest, in addition to the classical polyamines cadaverine, putrescine, spermine, and spermidine. This product of arginine decarboxylation has been suggested to regulate a variety of GPCR, ion channels and membrane transporters through largely unknown mechanisms that possibly include imidazoline receptor binding, and has been implicated in cognitive function, mood disorders, addiction, and diabetes (Molderings & Haenisch, 2012; Piletz et al., 2013) . Given that other imidazoline receptor ligands, although not agmatine, can activate TAAR1 (Hu et al., 2009) , whether there is a role for one or more other TAARs in agmatine-induced responses is an area for future study.
In addition to identifying endogenous ligands at individual TAARs, continued progress in the field will require the development of selective synthetic agonists and antagonists for each family member. The study of TAAR1 has considerably accelerated with the availability of highly selective agonists. However, the lack of membrane permeable antagonists continues to be problematic. With in silico models for TAARs now described, through which putative binding domains have been identified (Chiellini et al., 2015; Chiellini et al., 2016; Cichero et al., 2013; Cichero et al., 2014; Cichero et al., 2016; Kelemen et al., 2016; Reese et al., 2014; Tan et al., 2009) , it is hoped that some of these limitations can be overcome in the near future.
Demonstration of TAAR1 presence in human brain
Evidence from multiple approaches including mRNA and protein analysis, gene knock-out and knock-in, and brain exposure related pharmacodynamic effects of selective TAAR1 agonists, supports the expression of TAAR1 in the CNS of experimental animals. For human brain, however, the evidence is primarily from mRNA analyses with techniques such as RT-PCR (e.g. Borowsky et al., 2001) ; the lack of high quality antibody tools for human tissue, in combination with the unusually low expression of TAAR1, limiting the detection of the receptor protein. These mRNA-based methodologies are prone to contamination (e.g. Nelson et al., 2007) and poor sensitivity for low expression (b10 cDNA copies/μg of total RNA) receptors such as TAAR1 (e.g. Chiellini et al., 2012) . The presence of mRNA is also not necessarily a definitive surrogate for protein expression. Thus, based on the currently available data TAAR1 protein expression in the human brain may be regarded as equivocal. Resolution of this key issue will be critical for maintaining confidence in the rationale for the therapeutic utility of TAAR1 ligands for CNS related disorders.
There is much greater clarity in terms of the human peripheral tissue distribution of the TAAR1 protein due to the recent development of a specific anti-human TAAR1 antibody (Raab et al., 2016) and further facilitated by the approximate one order of magnitude higher mRNA levels seen in these tissues (Borowsky et al., 2001; Chiellini et al., 2012) . Here TAAR1 expression is largely associated with the β-cells of the pancreas, the stomach, and the small intestine, but not other peripheral tissues such as heart, liver and kidney (Raab et al., 2016) , aligning well with the expression pattern previously seen in mice (Revel et al., 2013) . With the growing appreciation of a functional gut-brain axis, the incretin-like effects of TAAR1 agonists previously described (see Section 3.5) should be borne in mind when the compounds are administered systemically, as they may contribute an additional level towards the CNS effects of TAAR1 ligands. For example GLP-1 can cross the blood brain barrier and stimulate GLP-1 receptors, which have been reported to be present in both animal and human brain tissue. In addition to metabolic effects, central GLP-1 receptors have been suggested to play a role in neuroprotection and in facilitating cognitive and affective function (McIntyre et al., 2013) . This, at least on face value, is not dissimilar to some of the CNS behavioural effects observed with TAAR1 agonists. With endogenous TAAR1 ligand levels readily affected by the commensal and non-commensal microbiota (see Section 4.6), such effects may well have relevance to the determination of the gut-brain interactome, and the role that the intestinal microbiota can play in regulating mental health. Clearly, further research is required to clarify the human brain expression pattern of TAAR1, as well as the potential role and relative contribution of the peripheral TAAR1 system towards TAAR1 mediated changes in CNS activity.
Clarification of TAAR cellular distribution
Although recent years have seen considerable progress made in the determination of the cellular distribution of TAAR1, little is known about other TAARs. Even where cellular distribution has been described, this has rarely been independently validated. This lack of clarity on the cellular distribution of individual TAARs has severely hampered the determination of their putative physiological roles. Not only are there minimal differences between the individual isoforms and very low expression levels, but there is considerable species variation in the functional TAAR complement present. As such not only is the highest stringency and selectivity of reagents required, but the translation of findings from experimental models to humans is difficult. This requires that considerable caution be exercised in interpreting initial findings, particularly if the species-specific selectivity of reagents has not been carefully described. Such problems have already been seen in the determination of TAAR1 functions, with initial reports of TAAR1 cellular distribution unable to be verified in other species, or with more selective reagents. In particular high quality antibodies for individual TAARs are lacking and it will only be with the availability of highly selective antibodies for each TAAR that maintain activity and selectivity in multiple species that current controversies surrounding the cellular distribution of TAARs can begin to be resolved.
TAAR effects throughout the body
With a clearer understanding of the cellular distribution of TAAR isoforms studies examining the role of each TAAR in individual tissues will be facilitated. Currently almost all attention has focussed on TAAR1 and its role in the brain, although the highest expression levels of this isoform are found in pancreatic β-cells. The role of peripheral TAAR1 in controlling energy metabolism has begun to be examined (Adriaenssens et al., 2015; Raab et al., 2016) , and this represents an exciting new avenue in the study of TAAR1 function. In addition, there is now sufficient evidence to suggest a more concerted examination of the role of TAAR1 (and potentially other TAARs) in the regulation of immune function is warranted. Confirmation of a role for one or more TAARs in the regulation of leukocyte function would open interesting new research directions. In particular trace amine levels are readily modified by the intestinal microbiota, either via conversion of precursor amino acids to trace amines, or degradation of trace amines (Mazzoli & Pessione, 2016) . With precursors and trace amines themselves found in commonly ingested foodstuffs, microbiota modified trace amine levels may represent a novel molecular mechanism for food-induced inflammatory reactions. Further, many endogenous TAAR ligands are volatile, and local immune system activation following TAAR activation potentially represents a novel mechanism of pulmonary inflammatory responses to environmental cues, such as in hypersensitivity pneumonitis. With selective agonists at individual TAARs becoming available testing of such possibilities should be readily completed.
Outside of TAAR1, almost all studies of other TAARs have focussed on their role in the detection of environmental olfactory cues. With mounting evidence that these TAARs are also present outside of the olfactory apparatus it will become important that studies specifically address the physiological effects of such TAAR isoforms, and distinguish between in vivo effects that are directly downstream of olfactory TAAR activation and those that are due to the entry of volatile TAAR ligands into the systemic circulation. This is particularly important given the relative ease with which at least some trace amines are able to cross cellular membranes (Berry et al., 2013) .
Role of TAAR1 in COMT polymorphism phenotypes
There is a growing interest in the role of catechol-O-methyl transferase (COMT; EC 2.1.1.6) polymorphism, in particular the Val158Met genotype, as a susceptibility factor for a variety of neuropsychiatric disorders, including schizophrenia, affective disorders, anxiety disorders, attention deficit hyperactivity disorder and drug abuse (Gatt, Burton, Williams, & Schofield, 2015) . The homozygous Val genotype is associated with a marked increase in enzyme activity. Such studies have focussed almost exclusively on the altered extracellular metabolism of dopamine and noradrenaline caused by the polymorphisms. The identification of O-methyl metabolites as TAAR1 agonists suggests that the situation may be more complex. O-methyl metabolites such as 3-methoxytyramine can no longer be viewed as inactive metabolites, and alterations in basal TAAR1 tone as a result of altered production of O-methyl derivatives of dopamine and noradrenaline should be considered. Investigation of the effects of TAAR1 knock-out and TAAR1 agonists on animal phenotypes associated with COMT polymorphisms would provide a good starting point for determining the role (if any) of altered trace aminergic tone in the clinical phenotypes associated with COMT polymorphisms.
Relationship of TAARs and their ligands to microbiota role in health and disease
In recent years there has been a growing appreciation of the role that the commensal microbiota plays in health and disease, including neuropsychiatric conditions (Lynch & Pedersen, 2016 ). An involvement in immune function (Honda & Littman, 2016; Thaiss, Zmora, Levy, & Elinav, 2016) , diet-induced metabolic dysfunction (Sonnenburg & Backhed, 2016) , and as a mediator of gut-brain relationships (Dinan & Cryan, 2015; Mazzoli & Pessione, 2016) have all been proposed. Identification of the chemical signals through which these interactions occur is an active area of research. As described, TAAR ligands and their precursors are readily produced and metabolized by the microbiota (Mazzoli & Pessione, 2016; Zhang & Davies, 2016) , and as the role of TAARs in cellular homeostasis are clarified, it is expected that microbiota regulation of TAAR ligand levels will become a growing area of research.
Research reagents and translational tools required
Given the therapeutic interest in TAAR1 it is perhaps not surprising that more reagents and tools have been developed for this receptor compared to other TAARs. Some of the most useful reagents include:
• Antibodies (anti-human TAAR1 antibody suitable for immunohistochemistry (Raab et al., 2016) and showing no cross reactivity with rat and mouse TAAR1; anti-rat TAAR1 antibody suitable for Western blot (Harmeier et al., 2015) showing no cross-reactivity with human and mouse TAAR1)
• Selective ligands (see Table 3 H-RO5192022) • TAAR1 knock-out mice and rats (Harmeier et al., 2015; Lindemann et al., 2008) • TAAR1 over-expressing mice (Revel, Moreau et al., 2012) The availability of these reagents has dramatically facilitated the development of knowledge on the putative physiological role of TAAR1 and its potential therapeutic utility. The same technological developments that are required to aid research into the function and potential therapeutic applications of other human TAAR subtypes, however, are absent. Furthermore, to support animal to human translational research, it is important to have technology that enables (i) compound exposure at the site of the molecular target (ii) determination of target engagement (e.g. PET ligands for receptor occupancy) and (iii) assessment of mechanism related pharmacodynamic effects (e.g. biomarkers). The availability of such tools will provide a more informed approach towards testing proof of concept, as well as rationale for dose selection, and increase the chances of successful clinical development (see Morgan et al., 2012) .
Conclusions
Although progress has been considerably slower than initially expected, recent years have seen significant advancements in understanding the molecular mechanisms of TAARs, in particular TAAR1, and its potential importance as a novel clinical target (Table 1) . TAAR1 is now well established to function in the regulation of dopaminergic activity, probably mediated through a D2-dopamine receptor heterodimerization induced promotion of biased signalling. Through such mechanisms selective TAAR1 ligands have shown beneficial effects in pre-clinical animal model systems with relevance to schizophrenia and drug abuse. Indeed, clinical safety testing of TAAR1 directed compounds for schizophrenia have been undertaken by two pharmaceutical companies, and in both instances TAAR1 confirmed as a viable pharmaceutical target. In addition, there is now good evidence that TAAR1 plays a role in sleep homeostasis, and beneficial effects have been seen in two animal models of narcolepsy. Outside of the CNS, growing evidence implicates TAAR1 as a novel target for the pharmacotherapy of metabolic disorders such as obesity and diabetes, although the molecular mechanisms by which TAAR1 activation leads to effects such as increased glucose-stimulated insulin secretion remains to be determined.
Although the above advances are impressive, there is still much that remains to be understood about TAARs, with the availability of suitable research reagents and translational tools the largest obstacle to further progress. With the recent advancements generating renewed interest in TAARs from the wider scientific community it is hoped that such reagents can be rapidly developed and made widely available. With the availability of new, selective, reagents it is anticipated that further progress in understanding the pharmacology and physiology of TAARs can be rapidly attained.
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